Cytokines as Predictive Factors of Response to Somatostatin Analogues in Patients with Neuroendocrine Tumour

#1770

Introduction: The somatostatin analogues are a major therapeutic advance in neuroendocrine tumor (NET) treatment and have multiple modulatory effects on the immune system.

Aim(s): The aim of this study was to evaluate the expression of several cytokines, at baseline and after administration of lanreotide (lan), in NET patients and NET cell lines.

Materials and methods: Ten NET patients were enrolled: 6 gastro-entero-pancreatic (GEP) NET, 2 bronchial carcinoids (BC), 2 breast NET. The expression of Interleukin 2, 4, 6, 10, TNF-α and IFN-γ were assessed on serum samples at T0 and after 10 up to 180 days of lan treatment, by cytometry. Lan effect on NET cell lines viability was evaluated by MTT and IL-6, IL-10 and TNF-α level by Western-Blotting.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Sciammarella C

Authors: Sciammarella C, Grimaldi A, Circelli L, Modica R, Pizza G,

Keywords: cytokines, neuroendocrine, cell,